Loading…
← CockpitCompetitor Analysis › 603439.SS GuiZhou SanLi Pharmaceutical Co., Ltd. Class AOpen in the cockpit ↗

GuiZhou SanLi Pharmaceutical Co., Ltd. Class A603439.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major
Momentum weak 36
Mkt cap
$583M
US dollars, full cap
Free float
39%
of shares outstanding
$/day
$17.1M
20-day average traded
Fwd P/E
26.8×
forward earnings
ROIC−WACC
-4.0 pp
WACC 9.1%
Hurdle
-1 pp
Req g minus delivered
Next earnings
161 days
28 Apr 2027
Close · CNYCN¥9.76
1D-2.4%
1W-10.5%
1M-16.6%
3M-24.5%
6M-19.8%
YTD-16.6%
1Y-19.5%
ATR %5.7%
52w lowhigh44.1% off high

What GuiZhou SanLi Pharmaceutical does

Employees: 1,887

GuiZhou SanLi Pharmaceutical at a glance

Size GuiZhou SanLi Pharmaceutical (603439.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $583M, the 3318th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥9.76 on 18 Nov 2026.

Performance Over six months the shares fell 19.8%, against -29.5% for the median peer and -20.0% for the China market (cap-weighted) — 4th highest of 20 in its peer set.

Growth Revenue fell 5.7% over the last twelve months (peer median -2.2%); the operating margin is 5.0% (peer median -2.3%).

Valuation It trades at 26.8× forward earnings against a peer median of 10.8× (4th most expensive of 9).

Price implies For today's price to make sense, revenue must grow about 21% a year for seven years (Req g). Recent delivered growth is +22%, so the hurdle is -1 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 4.0 points below its cost of capital (9.1% WACC).

Next results Next results expected around 28 Apr 2027 (exchange calendar; dates can move).

Relative performance

8010012021 May 202621 Aug 202618 Nov 2026603439.SS 76Peer median 74
Six months, rebased to 100: GuiZhou SanLi Pharmaceutical against the median of its 20 peers (local-currency closes).

GuiZhou SanLi Pharmaceutical financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥1.64BCN¥1.69BCN¥2.13BCN¥1.62BCN¥1.19B
Revenue growth—-21%+31%+36%—
Gross profitCN¥1.20BCN¥1.14BCN¥1.44BCN¥1.16BCN¥843M
EBITDAn/aCN¥262MCN¥400MCN¥307MCN¥222M
Net incomeCN¥52.8MCN¥46.3MCN¥274MCN¥293MCN¥201M
Free cash flowCN¥183MCN¥139MCN¥63.5MCN¥169MCN¥175M
Capital expenditureCN¥22.9MCN¥25.8MCN¥45.2MCN¥109MCN¥120M
Total debtCN¥668MCN¥795MCN¥728MCN¥610MCN¥235M

Quarterly statements and history in the cockpit →

GuiZhou SanLi Pharmaceutical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+100%-25%0%+25%+50%CGEM2157474322563613300147IMMXALMSENTXDBV002793603567603439.SS6-month return →1-month return →
Up and to the right = strong over both horizons. GuiZhou SanLi Pharmaceutical is the large dot.

Fundamentals: revenue growth against valuation

-50%0%+50%20×40×21573613600976301096688356185750603567002393603439.SSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. GuiZhou SanLi Pharmaceutical is the large dot.

Capital: growth delivered against growth the price implies

-20%0%+20%+40%-25%0%25%50%3613300147600976300233688356002793603567002393603439.SSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. GuiZhou SanLi Pharmaceutical is the large dot.

GuiZhou SanLi Pharmaceutical competitors and peer comparison

How GuiZhou SanLi Pharmaceutical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

GuiZhou SanLi Pharmaceutical against its 20 peers (data as of 18 Nov 2026)
Measure603439.SSPeer medianRank in peer set
1-month return-16.6%-11.8%7th lowest of 20
6-month return-19.8%-29.5%4th highest of 20
Distance from 52-week high-44.1%-43.9%10th lowest of 20
Revenue growth (TTM)-5.7%-2.2%7th lowest of 17
Operating margin5.0%-2.3%6th highest of 15
Forward P/E26.8×10.8×4th most expensive of 9
Growth the price implies (Req g, 7 yrs)20.9%-1.0%3rd most demanding of 10
Growth delivered (Del g)+21.9%+2.8%highest of 10
Hurdle (Req g minus delivered)-1.0 pp+1.0 pp5th least demanding of 10
ROIC minus cost of capital-4.0 pp-6.6 pp6th highest of 13

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
GuiZhou SanLi Pharmaceutical 603439.SSChina$583M-20%-6%5%26.8×20.9%+21.9%
Cullinan Therapeutics CGEMUnited States$585M-37%n/an/an/an/an/a
Lepu Biopharma 2157.HKHong Kong$580M-43%+47%7%53.6×n/an/a
Oneness Biotech 4743.TWOTaiwan$580M-13%+19%-589%n/an/an/a
Abbisko Cayman 2256.HKHong Kong$578M-39%-83%-520%n/an/an/a
Beijing Tong Ren Tang Chinese Medicine 3613.HKHong Kong$577M-26%-21%32%10.2×-15.4%+2.8%
Xiangxue Pharmaceutical 300147.SZChina$591M-41%+3%-39%n/a50.4%-12.3%
Immix Biopharma IMMXUnited States$596M-20%n/an/an/an/an/a
Alumis ALMSUnited States$569M-80%-67%-5,375%n/an/an/a
JIANMIN PHARMACEUTICAL 600976.SSChina$598M-14%-2%8%6.7×-6.2%+6.5%
Entera Bio ENTXUnited States$568M+163%-100%n/an/an/an/a
Hangzhou Bio-Sincerity Pharma-Tech 301096.SZChina$602M-38%+5%-30%54.0×n/an/a
Shandong Jincheng Pharmaceutical 300233.SZChina$604M-31%+2%4%n/a-0.6%-1.6%
DBV Technologies DBV.PAFrance$604M-46%n/an/an/an/an/a
Jenkem Technology 688356.SSChina$563M-30%+52%11%30.2×36.4%+11.2%
Zhong Zhu Healthcare 600568.SSChina$562M-22%-6%-34%n/an/an/a
Chongkundang 185750.KSSouth Korea$609M-27%+6%4%11.4×-6.6%+5.4%
Luoxin Pharmaceuticals Group Stock 002793.SZChina$609M-26%-10%-9%n/a-1.0%-17.9%
Achieve Life Sciences QUITUnited States$609Mn/an/an/an/an/an/a
HeiLongJiang ZBD Pharmaceutical 603567.SSChina$610M-39%-82%n/a5.4×9.1%-25.1%
Tianjin Lisheng Pharmaceutical 002393.SZChina$557M-24%-3%7%9.0×-5.8%+4.1%

Questions

Which companies are GuiZhou SanLi Pharmaceutical's closest peers?
The cockpit's peer set: Cullinan Therapeutics (CGEM), Lepu Biopharma (2157.HK), Oneness Biotech (4743.TWO), Abbisko Cayman (2256.HK), Beijing Tong Ren Tang Chinese Medicine (3613.HK), Xiangxue Pharmaceutical (300147.SZ), Immix Biopharma (IMMX), Alumis (ALMS).
Is GuiZhou SanLi Pharmaceutical expensive compared with its peers?
On forward p/e it trades at 26.8× against a peer median of 10.8×, 4th most expensive of 9 in its peer set. For today's price to make sense, revenue must grow about 21% a year for seven years (Req g). Recent delivered growth is +22%, so the hurdle is -1 pp: the price already allows for a slowdown.
How has GuiZhou SanLi Pharmaceutical stock performed?
Over six months to 18 Nov 2026 the shares returned -19.8% against -29.5% for the median peer; over one year -19.5%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.